Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Keratin, type II cytoskeletal 2 epidermal (KRT2) is a structural protein found predominantly in the upper spinous layer of epidermal keratinocytes, where it plays a critical role in the cytoskeleton and terminal differentiation of skin cells[1][3][2]. It is a member of the type II (basic or neutral) keratin family and forms heterodimers with type I keratins to assemble into intermediate filaments that maintain the integrity and resilience of epidermal tissue[4][6]. KRT2 expression is a hallmark of terminally differentiating suprabasal keratinocytes, especially in mechanically stressed epithelia such as the palms, soles, and other thick skin regions[2]. Mutations in KRT2 disrupt keratin filament structure, leading to epidermal fragility syndromes such as ichthyosis bullosa of Siemens and epidermolytic hyperkeratosis[1][3]. KRT2 is not considered a classic receptor, enzyme, or pharmacologic target, but its expression serves as a marker for keratinocyte differentiation and some skin pathologies[6][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Keratin, type II cytoskeletal 2 epidermal (KRT2).